Search results
Boston Scientific exec sells over $2.5 million in stock By Investing.com
Investing.com· 3 days agoBoston Scientific Corporation (NYSE:BSX) saw significant stock transactions by one of its top...
Boston Scientific (BSX) mCRM System Study Outcome Favorable
Zacks via Yahoo Finance· 7 days agoBoston Scientific Corporation BSX recently presented favorable six-month results from the ongoing...
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
Zacks via Yahoo Finance· 7 days agoShares of Boston Scientific Corporation BSX scaled a new 52-week high of $74.94 on May 17, before...
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
Zacks via Yahoo Finance· 4 days agoBoston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand...
What Drove A Nearly 2x Rise In Boston Scientific’s Profits?
Forbes· 5 days agoBoston Scientific (NYSE: BSX) saw its net income expand by $0.9 billion or 145% y-o-y to $1.6 billion in 2023. This can primarily be attributed to an expansion of its operating margin and lower ...
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
Zacks· 4 days agoCentene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
Zacks via Yahoo Finance· 5 days agoKey Picks Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Boston ...
Here's Why You Should Retain Edward Lifesciences (EW) for Now
Zacks· 3 days agoFree Report) is well poised for growth in coming quarters, backed by the strength of a differentiated portfolio of advanced therapies. The company continues to witness strong performance of ...
Tempe biotech firm Nectero lands $96M VC investment to support clinical trials
The Business Journals· 6 days agoNectero Medical, which focused on heart disease treatments, has closed a $96 million series D round...
Boston Scientific (NYSE:BSX) Upgraded by StockNews.com to Buy
ETF DAILY NEWS· 3 days agoNeedham & Company LLC upped their target price on Boston Scientific from $71.00 to $82.00 and gave the stock a buy rating in a research note on Wednesday, April 24th. Barclays increased their ...